Search Results

• • 924 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Select Cervarix

  1

  Cervarix

  From:Physician Assistants' Prescribing Reference (Vol. 17, Issue 1)

  Spring 2010201 words Brief article, Drug ... Company: GlaxoSmithKline Rx Pharmacologic class: Vaccine (HPV) Active ingredient: Bivalent human papillo-mavirus (HPV) vaccine types 16 and 18 vaccine; recombinant; aluminum adsorbed; susp for IM inj;...
• Select Cervarix

  2

  Cervarix

  From:Nurse Practitioners' Prescribing Reference (Vol. 17, Issue 1) Peer-Reviewed

  Spring 2010200 words Brief article Company: GlaxoSmithKline Rx Pharmacologic class: Vaccine (HPV) Active ingredient: Bivalent human papillomavirus (HPV) vaccine types 16 and 18 vaccine; recombinant; aluminum adsorbed; susp for IM inj;...
• Select FDA approves Gardasil 9 vaccine

  3

  FDA approves Gardasil 9 vaccine

  From:Nurse Practitioners' Prescribing Reference (Vol. 22, Issue 1) Peer-Reviewed

  Spring 201588 words Brief article 1260LThe FDA has approved Gardasil 9 (9-valent human papillomavirus types, recombinant; Merck) vaccine for the prevention of cervical, vulvar, vaginal, anal cancers, and for the prevention of genital warts caused by nine...
• Select Adequacy of fine-needle aspiration specimens for human papillomavirus infection molecular testing in head and neck squamous cell carcinoma

  4

  Adequacy of fine-needle aspiration specimens for human papillomavirus infection molecular testing in head and neck squamous cell carcinoma

  Authors:Ricardo Lastra, Michelle Pramick, Megan Nakashima, Gregory Weinstein, Kathleen Montone, Virginia LiVolsi, et al.From:CytoJournal (Vol. 10, Issue 1) Peer-Reviewed

  January-December 20133,259 words Report 1530LByline: Ricardo. Lastra, Michelle. Pramick, Megan. Nakashima, Gregory. Weinstein, Kathleen. Montone, Virginia. LiVolsi, Zubair. Baloch Background: Head and neck squamous cell carcinoma is often associated with human...
• Select Monitoring the coverage and impact of human papillomavirus vaccine--report of WHO meeting, November 2009/Surveillance de la couverture et des effets du vaccin antipapillomavirus humain--rapport d'une reunion de l'OMS, novembre 2009

  5

  Monitoring the coverage and impact of human papillomavirus vaccine--report of WHO meeting, November 2009/Surveillance de la couverture et des effets du vaccin antipapillomavirus humain--rapport d'une reunion de l'OMS, novembre 2009

  From:Weekly Epidemiological Record (Vol. 85, Issue 25)

  June 18, 20106,634 words Report 1850LWHO recommends that routine vaccination against human papillomavirus (HPV) be included in national immunization programmes provided that (i) the prevention of cervical cancer or other HPV-related diseases constitutes a...
• Select Cervical cancer screening & HPV vaccination: a comprehensive approach to cervical cancer control

  6

  Cervical cancer screening & HPV vaccination: a comprehensive approach to cervical cancer control

  Authors:Partha Basu and Debjani ChowdhuryFrom:Indian Journal of Medical Research (Vol. 130, Issue 3) Peer-Reviewed

  Sept. 20093,896 words Report 1480LIndia with its highest share of global burden of cervical cancer has to implement a population based cervical cancer control program to reduce the number of deaths. There are new screening options available like visual...
• Select Human papillomavirus vaccines WHO position paper/Vaccins anti-papillomavirus humain Note d'information de l'OMS

  7

  Human papillomavirus vaccines WHO position paper/Vaccins anti-papillomavirus humain Note d'information de l'OMS

  From:Weekly Epidemiological Record (Vol. 84, Issue 15)

  Apr. 10, 200913,035 words Report 1880LIn accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and vaccine combinations against diseases that have an...
• Select GP HPV jabs

  8

  GP HPV jabs

  From:Community Practitioner (Vol. 82, Issue 6) Peer-Reviewed

  June 2009255 words Brief article 1450LUnite/CPHVA has raised concerns that GPs are administering the human papillomavirus (HPV) vaccine because school nurses are too stretched. Unite/CPHVA professional officer Ros Godson stated: 'Despite the fact that...
• Select Introducing HPV vaccine in developing countries - addressing the challenge

  9

  Introducing HPV vaccine in developing countries - addressing the challenge

  Authors:Prianka Mukhopadhyay and Bhaskar PaulFrom:Indian Journal of Community Medicine (Vol. 34, Issue 4) Peer-Reviewed

  October-December 2009912 words Report Byline: Prianka. Mukhopadhyay, Bhaskar. Paul Sir, Vaccines have played a crucial role in preventing infectious disease-associated morbidity and mortality, worldwide. Vaccinations have achieved several milestones...
• Select Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix[TM]]: profile report

  10

  Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix[TM]]: profile report

  Authors:Susan J. Keam and Diane M. HarperFrom:BioDrugs (Vol. 22, Issue 3) Peer-Reviewed

  May-June 20082,953 words Article 3250LWorldwide, cervical cancer is the second most common cancer in women after breast cancer. [2,3] Current statistical analyses estimate that in 2002, 493 000 new cases of invasive cervical cancer were diagnosed and that...
• Select A sexual health prevention priority

  11

  A sexual health prevention priority

  Authors:Stephen Peckham and Alison HannFrom:Bulletin of the World Health Organization (Vol. 86, Issue 6) Peer-Reviewed

  June 2008972 words Clinical report 1720LWittet and Tsu are right to point to the link between cervical cancer deaths and achieving the MDGs and the inequity in the burden of cervical cancer between developed and developing countries. Any programme that...
• Select Evaluating global health partnerships: A case study of a Gavi HPV vaccine application process in Uganda

  12

  Evaluating global health partnerships: A case study of a Gavi HPV vaccine application process in Uganda

  Authors:Carol Kamya, Jessica Shearer, Gilbert Asiimwe, Emily Carnahan, Nicole Salisbury, Peter Waiswa, et al.From:International Journal of Health Policy and Management (Vol. 6, Issue 6) Peer-Reviewed

  June 1, 20179,496 words Report 1650LAbstract Background: Global health partnerships have grown rapidly in number and scope, yet there has been less emphasis on their evaluation. Gavi, the Vaccine Alliance, is one such public-private partnership; in...
• Select A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.

  13

  A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.

  Authors:Yi Zeng, Anna-Barbara Moscicki, Vikrant V. Sahasrabuddhe, Francisco Garcia, Heide Woo, Chiu-Hsieh Hsu, et al.From:BMC Cancer (Vol. 19, Issue 1) Peer-Reviewed

  Apr. 1, 20194,705 words Report 1600LBackground Human papillomavirus (HPV) vaccines are indicated for the prevention of cancers and genital warts caused by vaccine-covered HPV types. Although the standard regimen requires a two or three-dose vaccine...
• Select Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV

  14

  Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV

  Authors:Simona Di Mario, Vittorio Basevi, Pier Luigi Lopalco, Sara Balduzzi, Roberto D'Amico, and Nicola MagriniFrom:Journal of Immunology Research (Vol. 2015) Peer-Reviewed

  Annual 20156,103 words Report 1390LBackground. When the bivalent and the quadrivalent HPV vaccines were marketed they were presented as having comparable efficacy against cervical cancer. Differences between the vaccines are HPV types included and...
• Select The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study

  15

  The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study

  Authors:Tetsuji Kurokawa, Makoto Yamamoto, Toshimichi Onuma, Hideaki Tsuyoshi, Akiko Shinagawa, Yoko Chino, et al.From:BMC Cancer (Vol. 20, Issue 1) Peer-Reviewed

  Nov. 3, 20202,292 words Report 1470LBackground In general, human papillomavirus (HPV) vaccines have demonstrated efficacy in young women worldwide, but there is limited evidence on the efficacy of the quadrivalent HPV6/11/16/18 vaccine in adult women...
• Select The feasibility of new HPV/DNA test as a primary cervical cancer screening method among 35- years- old ever-married women in Kalutara district; a cross-sectional study.

  16

  The feasibility of new HPV/DNA test as a primary cervical cancer screening method among 35- years- old ever-married women in Kalutara district; a cross-sectional study.

  Authors:K. C. M. Perera, N. Mapitigama, and HTCS AbeysenaFrom:BMC Public Health (Vol. 21, Issue 1) Peer-Reviewed

  Jan. 13, 20214,732 words Report 1580LBackground Cervical cancer is the second commonest female cancer in Sri Lanka. Two major drawbacks of the present cervical cancer screening programme are the suboptimal sensitivity of the pap smear and the low...
• Select Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers

  17

  Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers

  Authors:Stanley MF. Luchters, Davy Vanden Broeck, Matthew F. Chersich, Annalene Nel, Wim Delva, Kishor Mandaliya, et al.From:BMC Infectious Diseases (Vol. 10) Peer-Reviewed

  Jan. 26, 20106,178 words Survey Background Human papillomavirus (HPV) and HIV are each responsible for a considerable burden of disease. Interactions between these infections pose substantial public health challenges, especially where HIV...
• Select Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum

  18

  Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum

  Authors:Thomas O. Kohl, Inga I. Hitzeroth, Neil D. Christensen, and Edward P. RybickiFrom:BMC Biotechnology (Vol. 7) Peer-Reviewed

  Sept. 12, 20078,651 words Report 1500LBackground We have investigated the possibility and feasibility of producing the HPV-11 L1 major capsid protein in transgenic Arabidopsis thaliana ecotype Columbia and Nicotiana tabacum cv. Xanthi as potential...
• Select Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination

  19

  Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination

  Authors:Ellinor Ostensson, Maria Froberg, Amy Leval, Ann-Cathrin Hellstrom, Magnus Backlund, Niklas Zethraeus, et al.From:PLoS ONE (Vol. 10, Issue 9) Peer-Reviewed

  Sept. 23, 20157,481 words Report 1620LObjective Costs associated with HPV-related diseases such as cervical dysplasia, cervical cancer, and genital warts have not been evaluated in Sweden. These costs must be estimated in order to determine the potential...
• Select HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues

  20

  HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues

  Authors:Margaret A Stanley, David M Winder, Jane C Sterling, and Peter KC GoonFrom:BMC Cancer (Vol. 12, Issue 1) Peer-Reviewed

  Sept. 8, 20123,260 words Letter to the editor 1660LBackground Human papillomavirus (HPV) is well known as the major etiological agent for ano-genital cancer. In contrast to cervical cancer, anal cancer is uncommon, but is increasing steadily in the community over the...